Gail McIntyre, PhD, DABT

Chief Scientific Officer

Gail McIntyre has been Aravive’s Chief Scientific Officer since February 2019.  Prior to that, she was the Company’s Senior Vice President of Research and Development since October 2018 and previously served as Aravive Biologics, Inc.’s Senior Vice President of Research and Development since January 2017 and a consultant to Aravive Biologics, Inc. from August 2016 until January 2017. Dr. McIntyre also served as a principal at IntelliDev Consulting, LLC providing consulting services to several biotechnology companies from January 2014 to January 2017, and served as VP of Development for Meryx, Inc from January 2014 until January 2016. Dr. McIntyre held the position of Senior Vice President of Research at Furiex Pharmaceuticals, Inc. from April 1, 2010 until December 2014 and served as head of Pharmaceutical Product Development LLC’s compound partnering business for 8 years prior to that. Dr. McIntyre has authored more than 30 regulatory submissions and is a board certified toxicologist with extensive experience in moving compounds through lead optimization and clinical development onto the market. Her experience covers multiple therapeutic areas including oncology (including immune-oncology), infectious diseases, central nervous system, gastrointestinal, and metabolic/endocrine as well as various therapies including small drugs, treatment vaccines, antibodies, immunoconjugates and peptide mimetics. Dr. McIntyre is also board certified in Clinical Pathology (hematology and clinical chemistry) by the American Society of Clinical Pathology. Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.